Mieloma Múltiplo: a propósito de um caso raro de gamapatia biclonal IgD/lambda – Abordagem diagnóstica e atitudes terapêuticas
Keywords:
multiple myeloma, aetiology, diagnosis, complications, prognosis, treatmentAbstract
The case report of a multiple myeloma, in a 74 years old man, is presented. Data from seric
immunoglobulin, seric and urinary protein immunofixation and bone marrow aspiration are the main
support for the diagnosis. The aetiology, clinical, laboratorial and radiologic characteristics, specific
complications, prognostic factors, results of contemporary therapy and future therapeutic approaches
are discussed.
Downloads
References
Kyle RA. Plasma cell disorders. In: Goldman L et al. Cecil Textbook of Medicine. 21th ed. Philadelphia WB Saunders Company, 2000; 13 (181): 977-987.
Drach J et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126 (8): 441-7.
Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukaemia. Leuk Res 2000; 24 (8): 681-703.
Gado K et al. Role of Interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000; 24 (4); 195-209.
Kelly T et al. Matrix metalloproteinases in multiple mieloma. Leuk Lymphoma 2000 ; 37 (3-4) : 273-281.
Beaudreuil J, Orcel P. Bone hyperresorption in multiple myeloma. Press Med 2000; 29 (9): 492-497.
Longo DL. Plasma cell disorders. In : Braunwald E et al. Harrison´s Principles of Internal Medicine. 14th ed. New York. McGraw-Hill 1998; 114: 712-724.
Barlogie B et al. Plasma cell myeloma. In: Beutler E. et al. Williams Hematology. 6th ed. New York. McGraw-Hill 2001; 106:1279-1300.
Cathomas G. Human herpes virus 8: a new virus discloses its face. Virchows Arch 2000; 436 (3): 195-206.
Chesi M et al. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol 2000; 11 suppl 1: 131-135.
Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336 (23): 1657-1663.
Treon SP et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11 Suppl 1: 107-111.
Boccadoro M, Pileri A. Diagnosis, prognosis and standard treatment of multiple myeloma. Hematol Oncol Clin North America 1997; 11 (1): 111-125.
Sinohara H. Does catalytic activity of Bence-Jones proteins contribute to the pathogenesis of multiple mieloma?. Appl Biochem Biotechnol 2000; 83 (1-3); 85-92; discussion 93-4, 145-153.
Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer 2000; 88 (Suppl 12): 3022-3032.
Clezardin P et al. Mechanisms of action of biphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000; 67 (1): 22-29.
Clezardin P. Bone hyperresorption in bone metastases. Presse Med 2000; 29 (9): 487-491.
Rodman GD Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer Sup. 1997; 80 (8): 1557-1562.
Halczuk I et al. Myelomatous meningitis : a case report. Neurol Neurochir Pol 1999 ; 33 (6): 1425-1433.
Dimopoulos MA et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma.Blood 2000; 96 (6): 2037-2044.
Kyle RA. The role of high dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 2000; 11 Suppl 1: 55-58.
Blad J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?. Med Oncol 2000; 17 (2): 77-84.
Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Haematol 2000; 64 (6): 359-367.
Shtil AA et al. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma 2000; 38 (1-2): 59-70.
Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247 (5): 521-534.
Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells toimmunotherapy of multiple myeloma. Med Oncol 2000; 17 (1): 2-15.
Dimopoulos MA et al. Thalidomide and dexamethasone combination for refractory multiplemyeloma. Ann Oncol 2001; 991-995.
Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 1999; 12 (1-2) 171-191.
Gahrton G, Bjorkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med 2000; 248 (3): 185-201.
Riera L, Koziner B. Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells. Medicina (B Aires) 2000; 60 (2): 259-269.
Attal M et al. Single versus double transplant in myeloma: a randomized trial of the “Inter Group Grancais du myelome”. France.
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
